As the healthcare industry reforms to convert the current fee-for-service model to fee-for-value model, intense focus has been placed on the reduction in patient complications, and number and length of hospital stay. Interventional cardiology, in particular, is at a pivot point with remarkable evolution taking place in device technology, operator techniques, and clinical safety and efficacy. Enormous advances have been made in the treatment of coronary artery disease, and the era of 'stent implantation' is upon today’s patients. Moreover, the advent of drug-eluting stents (DES) has considerably changed and revolutionized the interventional landscape, and made angioplasty more predictable, as such, catalyzing the growth of the drug-eluting stents market.
In recent years, acceleration in device development, advances in adjunctive pharmacology, and improved information systems have turned the spotlight on the drug-eluting stents market. According to the latest research by Transparency Market Research (TMR)on the drug eluting stents market, the worldwide sales of drug-eluting stents will reach ~US$ 5.5 billion in 2019, recording a promising CAGR of ~5% during the period of 2019-2027.
Rapid advancements in stent designs and delivery systems have made stenting much easier to integrate in interventional milieu – reducing the cases of restenosis, even for the most complex lesions. However, with the occurrence of stent thrombosis, manufacturers in the drug-eluting stents market are focusing on the development of newer generation of drug-eluting stents that facilitate the eradication of this fatal outcome. Bioresorbable stent (BRS) technology has been gaining increasing momentum in the most recent generation of drug-eluting stents, which are associated with significant reduction in the risk of early and late thrombosis.
While DES based on durable polymers continue to account for relatively high sales, manufacturers operating in the drug-eluting stents market are focusing on innovating and increasing the production of biodegradable polymer-based DES, as such polymers degrade efficiently after the elution of drugs. In addition, rising safety concerns regarding the usage of third-generation drug-eluting stents have prompted the development of fully-biodegradable or bioresorbable stents due to their potential advantages in decreasing inflammatory response, improving drug elution kinetics, and predictably inhibiting restenosis and late stent thrombosis.
Bioresorbable drug-eluting stents/scaffolds are likely to represent a crucial step in stent technology development, and provide the added benefit of completely degrading, allowing the recovery of vessel vasoreactivity and endothelial function. TMR’s analysts forecast that, the fourth-generation of drug-eluting stents will record an impressive CAGR of ~52% during the predefined timeframe.
While stringent regulatory requirements set by the FDA have long affected the commercialization of various drug-eluting stents in the United States, increased access to advanced technologies and successful outcomes in clinical trials have been recently influencing the FDA approvals of newer generation of products. For instance, in 2019, BIOTRONIK announced the FDA approval of its ultrathin Orsiro drug-eluting stent (DES) system, while the same device received its CE marking in 2011. Such factors, along with robust R&D on cardiovascular interventions and increase in demand for bioresorbable drug-eluting stents, are likely to play an important role in the strategic expansion of manufacturers in developed drug-eluting stents markets.
Leading stakeholders in the drug-eluting stents market continue to view developing countries in Asia Pacific from a target market perspective, on the account of increased healthcare expenditure per capita and favorable government initiatives to improve the industry’s infrastructure. However, the emergence of a large number of local players along with government reforms is playing a major role in deciding the prices of stents, which has represented a potential threat to the steady expansion of key players. For instance, price caps initiated by the National Pharmaceutical Pricing Authority (NPPA) in India has led to the withdrawal of DES systems by global manufacturers, while creating a golden opportunity for local players.
Analysts’ Viewpoint of the Drug-eluting Stents Market
Although significant advances have been made, the most reliable drug-eluting stent systems are yet to be developed, according to TMR’s analysts. Considering the risk of late thrombosis among patients, manufacturers will need to conduct larger trials and longer follow-ups to assess the effectiveness of their novel devices. According to TMR’s analysts, the success of key drug-eluting stents market players in developing countries with high pricing pressure will hinge on offering high-quality products at affordable prices. Local players, on the other hand, will need to focus on developing the latest generation of drug-eluting stents to retain and attract new segments of end users.
Introduction of Fully-bioresorbable Stents: A Key Driver
Increase in Prevalence of Cardiovascular Diseases Drives the Drug-eluting Stents Market
Global Drug-eluting Stents Market: Key Segments
Drug-eluting stents Market: Competition Landscape
Major companies profiled in the drug-eluting stents market report include
Adoption of Expansion Strategies by Major Players in Drug-eluting Stents Market
Drug-eluting Stents Market – Segmentation
The report provides an all-inclusive segmental analysis of the global drug-eluting stents market, which has been classified into seven broader categories – product, drug, generation, scaffold, application, end user, and region. Analysis of key geographies that account for growth opportunities or hold substantial share has also been included as part of the geographic analysis of the drug-eluting stents market.
|
Product |
Polymer-based
Polymer-free |
|
Drug |
Sirolimus Paclitaxel Zotarolimus Everolimus Biolimus Others |
|
Generation |
1st Generation 2nd Generation 3rd Generation 4th Generation |
|
Scaffold |
Cobalt-Chromium Platinum-Chromium Nitinol Biodegradable Others |
|
Application |
Coronary Diseases Peripheral Vascular Diseases |
|
End User |
Hospitals Ambulatory Surgical Centers |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Drug-eluting stents market is estimated to reach ~US$ 8.3 Bn in 2027
Drug-eluting stents market is expected to expand at a CAGR of ~5% during 2019 - 2027
Drug-eluting stents market is driven by increase in numbers of geriatric people, increase in research and development (R&D) activities and technological advancement
North America to be a Prominent Region in the global drug-eluting stents market over the forecast period
Key players in the drug-eluting stents market include Boston Scientific Corporation, Medtronic, Abbott, Biosensors International Group, Ltd ( Bluesail Medical Co., Ltd.), Biotronik, MicroPort Scientific Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug-eluting Stents Market
3.1. Market Overview
3.2. Introduction
3.3. Product Definition
3.4. Industry Evolution / Developments
4. Overview
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Global Drug-eluting Stents Market Analysis and Forecast, 2017–2027
5. Key Insights
5.1. Breakthrough Technologies in Drug-eluting Stents Market
5.2. Regulatory Approvals in Drug-eluting Stents Market
5.3. Strategic Approaches by Market Players (Acquisitions, Partnerships, and Distribution Agreements, etc.)
5.4. Product Launch
6. Global Drug-eluting Stents Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
6.3.1. Polymer-based
6.3.1.1. Biodegradable Polymers
6.3.1.2. Durable Polymers
6.3.2. Polymer-free
6.4. Global Drug-eluting Stents Market Attractiveness, by Product
7. Global Drug-eluting Stents Market Analysis and Forecast, by Drug
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
7.3.1. Sirolimus
7.3.2. Paclitaxel
7.3.3. Zotarolimus
7.3.4. Everolimus
7.3.5. Biolimus
7.3.6. Others
7.4. Global Drug-eluting Stents Market Attractiveness, by Drug
8. Global Drug-eluting Stents Market Analysis and Forecast, by Generation
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
8.3.1. 1st Generation
8.3.2. 2nd Generation
8.3.3. 3rd Generation
8.3.4. 4th Generation
8.4. Market Attractiveness, by Generation
9. Global Drug-eluting Stents Market Analysis and Forecast, by Scaffold Type
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
9.3.1. Cobalt Chromium
9.3.2. Platinum Chromium
9.3.3. Nitinol
9.3.4. Biodegradable
9.3.5. Others
9.4. Global Drug-eluting Stents Market Attractiveness, by Scaffold Type
10. Global Drug-eluting Stents Market Analysis and Forecast, by Application
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Global Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
10.3.1. Coronary Diseases
10.3.2. Peripheral Vascular Diseases
10.4. Global Drug-eluting Stents Market Attractiveness, by Application
11. Global Drug-eluting Stents Market Analysis and Forecast, by End-user
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Global Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.4. Global Drug-eluting Stents Market Attractiveness, by End-user
12. Global Drug-eluting Stents Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Global Drug-eluting Stents Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Global Drug-eluting Stents Market Attractiveness, by Country/Region
13. North America Drug-eluting Stents Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. North America Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
13.3.1. Polymer-based
13.3.1.1. Biodegradable Polymers
13.3.1.2. Durable Polymers
13.3.2. Polymer-free
13.4. North America Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
13.4.1. Sirolimus
13.4.2. Paclitaxel
13.4.3. Zotarolimus
13.4.4. Everolimus
13.4.5. Biolimus
13.4.6. Others
13.5. North America Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
13.5.1. 1st Generation
13.5.2. 2nd Generation
13.5.3. 3rd Generation
13.5.4. 4th Generation
13.6. North America Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
13.6.1. Cobalt Chromium
13.6.2. Platinum Chromium
13.6.3. Nitinol
13.6.4. Biodegradable
13.6.5. Others
13.7. North America Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
13.7.1. Coronary Diseases
13.7.2. Peripheral Vascular Diseases
13.8. North America Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
13.8.1. Hospitals
13.8.2. Ambulatory Surgical Centers
13.9. North America Drug-eluting Stents Market Value Forecast, by Country, 2017–2027
13.9.1. 1. U.S.
13.9.2. Canada
13.10. North America Drug-eluting Stents Market Attractiveness Analysis
13.10.1. By Product
13.10.2. By Drug
13.10.3. By Generation
13.10.4. By Scaffold Type
13.10.5. By Application
13.10.6. By End-user
13.10.7. By Country
14. Europe Drug-eluting Stents Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Europe Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
14.3.1. Polymer-based
14.3.1.1. Biodegradable Polymers
14.3.1.2. Durable Polymers
14.3.2. Polymer-free
14.4. Europe Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
14.4.1. Sirolimus
14.4.2. Paclitaxel
14.4.3. Zotarolimus
14.4.4. Everolimus
14.4.5. Biolimus
14.4.6. Others
14.5. Europe Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
14.5.1. 1st Generation
14.5.2. 2nd Generation
14.5.3. 3rd Generation
14.5.4. 4th Generation
14.6. Europe Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
14.6.1. Cobalt Chromium
14.6.2. Platinum Chromium
14.6.3. Nitinol
14.6.4. Biodegradable
14.6.5. Others
14.7. Europe Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
14.7.1. Coronary Diseases
14.7.2. Peripheral Vascular Diseases
14.8. Europe Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
14.8.1. Hospitals
14.8.2. Ambulatory Surgical Centers
14.9. Europe Drug-eluting Stents Market Value Forecast, by Country/Sub-region, 2017–2027
14.9.1. Germany
14.9.2. U.K.
14.9.3. France
14.9.4. Spain
14.9.5. Italy
14.9.6. Rest of Europe
14.10. Europe Drug-eluting Stents Market Attractiveness Analysis
14.10.1. By Product
14.10.2. By Drug
14.10.3. By Generation
14.10.4. By Scaffold Type
14.10.5. By Application
14.10.6. By End-user
14.10.7. By Country/Sub-region
15. Asia Pacific Drug-eluting Stents Market Analysis and Forecast
15.1. Introduction
15.2. Key Findings
15.3. Asia Pacific Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
15.3.1. Polymer-based
15.3.1.1. Biodegradable Polymers
15.3.1.2. Durable Polymers
15.3.2. Polymer-free
15.4. Asia Pacific Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
15.4.1. Sirolimus
15.4.2. Paclitaxel
15.4.3. Zotarolimus
15.4.4. Everolimus
15.4.5. Biolimus
15.4.6. Others
15.5. Asia Pacific Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
15.5.1. 1st Generation
15.5.2. 2nd Generation
15.5.3. 3rd Generation
15.5.4. 4th Generation
15.6. Asia Pacific Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
15.6.1. Cobalt Chromium
15.6.2. Platinum Chromium
15.6.3. Nitinol
15.6.4. Biodegradable
15.6.5. Others
15.7. Asia Pacific Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
15.7.1. Coronary Diseases
15.7.2. Peripheral Vascular Diseases
15.8. Asia Pacific Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
15.8.1. Hospitals
15.8.2. Ambulatory Surgical Centers
15.9. Asia Pacific Drug-eluting Stents Market Value Forecast, by Country/Sub-region, 2017–2027
15.9.1. China
15.9.2. Japan
15.9.3. India
15.9.4. Australia & New Zealand
15.9.5. Rest of Asia Pacific
15.10. Asia Pacific Drug-eluting Stents Market Attractiveness Analysis
15.10.1. By Product
15.10.2. By Drug
15.10.3. 15.9By Generation
15.10.4. By Scaffold Type
15.10.5. By Application
15.10.6. By End-user
15.10.7. By Country/Sub-region
16. Latin America Drug-eluting Stents Market Analysis and Forecast
16.1. Introduction
16.2. Key Findings
16.3. Latin America Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
16.3.1. Polymer-based
16.3.1.1. Biodegradable Polymers
16.3.1.2. Durable Polymers
16.3.2. Polymer-free
16.4. Latin America Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
16.4.1. Sirolimus
16.4.2. Paclitaxel
16.4.3. Zotarolimus
16.4.4. Everolimus
16.4.5. Biolimus
16.4.6. Others
16.5. Latin America Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
16.5.1. 1st Generation
16.5.2. 2nd Generation
16.5.3. 3rd Generation
16.5.4. 4th Generation
16.6. Latin America Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
16.6.1. Cobalt Chromium
16.6.2. Platinum Chromium
16.6.3. Nitinol
16.6.4. Biodegradable
16.6.5. Others
16.7. Latin America Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
16.7.1. Coronary Diseases
16.7.2. Peripheral Vascular Diseases
16.8. Latin America Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
16.8.1. Hospitals
16.8.2. Ambulatory Surgical Centers
16.9. Latin America Drug-eluting Stents Market Value Forecast, by Country/Sub-region, 2017–2027
16.9.1. Brazil
16.9.2. Mexico
16.9.3. Rest of Latin America
16.10. Latin America Drug-eluting Stents Market Attractiveness Analysis
16.10.1. By Product
16.10.2. By Drug
16.10.3. By Generation
16.10.4. By Scaffold Type
16.10.5. By Application
16.10.6. By End-user
16.10.7. By Country/Sub-region
17. Middle East & Africa Drug-eluting Stents Market Analysis and Forecast
17.1. Introduction
17.2. Key Findings
17.3. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
17.3.1. Polymer-based
17.3.1.1. Biodegradable Polymers
17.3.1.2. Durable Polymers
17.3.2. Polymer-free
17.4. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
17.4.1. Sirolimus
17.4.2. Paclitaxel
17.4.3. Zotarolimus
17.4.4. Everolimus
17.4.5. Biolimus
17.4.6. Others
17.5. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
17.5.1. 1st Generation
17.5.2. 2nd Generation
17.5.3. 3rd Generation
17.5.4. 4th Generation
17.6. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
17.6.1. Cobalt Chromium
17.6.2. Platinum Chromium
17.6.3. Nitinol
17.6.4. Biodegradable
17.6.5. Others
17.7. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
17.7.1. Coronary Diseases
17.7.2. Peripheral Vascular Diseases
17.8. Market Value Forecast, by End-user, 2017–2027
17.8.1. Hospitals
17.8.2. Ambulatory Surgical Centers
17.9. Market Value Forecast, by Country/Sub-region, 2017–2027
17.9.1. GCC Countries
17.9.2. South Africa
17.9.3. Rest of Middle East & Africa
17.10. Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis
17.10.1. By Product
17.10.2. By Drug
17.10.3. By Generation
17.10.4. By Scaffold Type
17.10.5. By Application
17.10.6. By End-user
17.10.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player – Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis by Company (2018)
18.3. Company Profiles
18.3.1. Boston Scientific Corporation
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Financial Overview
18.3.1.3. Product Portfolio
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Medtronic
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Financial Overview
18.3.2.3. Product Portfolio
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. Abbott
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Financial Overview
18.3.3.3. Product Portfolio
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Biosensors International Group, Ltd (Bluesail Medical Co., Ltd.)
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Strategic Overview
18.3.5. Biotronik
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Strategic Overview
18.3.6. MicroPort Scientific Corporation
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Financial Overview
18.3.6.3. Product Portfolio
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Terumo Corporation
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Financial Overview
18.3.7.3. Product Portfolio
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Cook
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Strategic Overview
18.3.9. STENTYS SA
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Financial Overview
18.3.9.3. Product Portfolio
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Medinol Ltd
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Strategic Overview
List of Tables
Table 01 Regulatory Approvals in Drug-eluting Stents Market (1/2)
Table 02 Regulatory Approvals in Drug-eluting Stents Market (2/2)
Table 03 Product Launch in Drug-eluting Stents Market
Table 04 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 05 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 06 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 07 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 08 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 09 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 10 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 11 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 12 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 13 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 14 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 15 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 16 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 17 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 18 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 19 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 20 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 21 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 22 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 23 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 24 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 25 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 26 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 27 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 28 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 29 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 30 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 31 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 32 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 33 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 34 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 35 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 36 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 37 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 38 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 39 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 40 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 41 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 42 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 43 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 44 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 45 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 46 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 47 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 48 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 49 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 50 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 51 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
List of Figures
Figure 01 Strategic Approaches by Market Players (Acquisitions, Partnerships, and Distribution Agreements, etc.) in Drug-eluting Stents Market (1/2)
Figure 02 Strategic Approaches by Market Players (Acquisitions, Partnerships, and Distribution Agreements, etc.) in Drug-eluting Stents Market (2/2)
Figure 03 Global Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 04 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Polymer-based, 2017–2027
Figure 05 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Polymer-free, 2017–2027
Figure 06 Global Drug-eluting Stents Market Attractiveness, by Product, 2019–2027
Figure 07 Global Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 08 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Sirolimus, 2017–2027
Figure 09 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Everolimus, 2017–2027
Figure 10 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Paclitaxel, 2017–2027
Figure 11 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Zotarolimus, 2017–2027
Figure 12 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biolimus, 2017–2027
Figure 13 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027
Figure 14 Global Drug-eluting Stents Market Attractiveness, by Drug, 2019–2027
Figure 15 Global Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 16 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 1st Generation, 2017–2027
Figure 17 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 2nd Generation, 2017–2027
Figure 18 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 3rd Generation, 2017–2027
Figure 19 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 4th Generation, 2017–2027
Figure 20 Global Drug-eluting Stents Market Attractiveness, by Generation, 2019–2027
Figure 21 Global Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 22 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cobalt Chromium, 2017–2027
Figure 23 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Platinum Chromium, 2017–2027
Figure 24 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nitinol, 2017–2027
Figure 25 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biodegradable, 2017–2027
Figure 26 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biolimus, 2017–2027
Figure 27 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027
Figure 28 Global Drug-eluting Stents Market Attractiveness, by Scaffold, 2019–2027
Figure 29 Global Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 30 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Coronary Diseases, 2017–2027
Figure 31 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Peripheral Vascular Diseases, 2017–2027
Figure 32 Global Drug-eluting Stents Market Attractiveness, by Application, 2019–2027
Figure 33 Global Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 34 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals, 2017–2027
Figure 35 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2017–2027
Figure 36 Global Drug-eluting Stents Market Attractiveness, by End User, 2019–2027
Figure 37 Global Drug-eluting Stents Market Value Share (%), by Region, 2018 and 2027
Figure 38 Global Drug-eluting Stents Market Attractiveness, by Region, 2019–2027
Figure 39 North America Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 40 North America Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 41 North America Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 42 North America Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 43 North America Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 44 North America Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 45 North America Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 46 North America Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 47 North America Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 48 North America Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 49 North America Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 50 North America Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 51 North America Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 52 North America Drug-eluting Stents Market Attractiveness Analysis, by Country, 2019–2027
Figure 53 North America Drug-eluting Stents Market Value Share Analysis, by Country, 2018 and 2027
Figure 54 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 55 Europe Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 56 Europe Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 57 Europe Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 58 Europe Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 59 Europe Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 60 Europe Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 61 Europe Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 62 Europe Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 63 Europe Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 64 Europe Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 65 Europe Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 66 Europe Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 67 Europe Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 68 Europe Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 69 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 70 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 71 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 72 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 73 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 74 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 75 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 76 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 77 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 78 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 79 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 80 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 81 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 82 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 83 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 84 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 85 Latin America Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 86 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 87 Latin America Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 88 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 89 Latin America Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 90 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 91 Latin America Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 92 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 93 Latin America Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 94 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 95 Latin America Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 96 Latin America Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 97 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 98 Latin America Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 99 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 100 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 101 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 102 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 103 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 104 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 105 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 106 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 107 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 108 Figure 43: Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 109 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 110 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 111 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 112 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 113 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drug-eluting Stents Market Trends, 2019-2027
